- A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
- RSI is at a high level of 71. A high level of RSI indicates the stock is overbought.
- MACD is crossing MACD signal line at 0.3. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Emergent Biosolutions saw its IBD SmartSelect Composite Rating rise to 97 Wednesday, up from 92 the day before.
Company Announcement * Genmab to receive USD 40 million milestone payment from AbbVie * Milestone triggered by progress in Phase 3 study of epcoritamab in diffuse large B-cell lymphomaCopenhagen, Denmark; January 13, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that it has reached the first milestone in its collaboration with AbbVie. A USD 40 million milestone payment was triggered by the first patient dosed in the Phase 3 study of subcutaneous epcoritamab versus investigator’s choice of c...
Media Release Copenhagen, Denmark, January 6, 2021Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 39th Annual J.P. Morgan Healthcare Conference at 10:00 AM EST / 4.00 PM CET on January 13, 2021. The live and archived webcast of the presentation will be available on Genmab’s website at https://ir.genmab.com/events-and-presentationscontent.About Genmab Genmab is an international biotechnology company with a core purpose ...
Genmab (GMAB) starts the global phase III innovaTV 301 study evaluating tisotumab vedotin versus chemotherapy for treating recurrent/metastatic cervical cancer.
Company AnnouncementCopenhagen, Denmark; January 5, 2021 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the compan...
Media Release COPENHAGEN, Denmark, Jan. 04, 2021 * Initiation of a global phase 3 trial for tisotumab vedotin versus investigator’s choice chemotherapy in recurrent or metastatic cervical cancer Genmab A/S (Nasdaq: GMAB) announced today the initiation of innovaTV 301 trial, a global phase 3 study to evaluate the efficacy of tisotumab vedotin compared to chemotherapy in patients with recurrent or metastatic cervical cancer who have received one or two prior lines of systemic therapy. Th...
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs, Skyrizi and Rinvoq are seeing strong sales uptake.
A Relative Strength Rating upgrade for Revance Therapeutics shows improving technical performance. Will it continue?